The process of developing drugs and bringing them to the market can be a lengthy and costly one. It can easily take 10 to 15 years for a drug to go from its early stages to the point where the public can consume it, and knowing what drugs a company is working on can help you determine whether it's a solid investment. When a pharmaceutical company is said to have drugs in the pipeline, it means it is still doing research and performing tests on those formulas' safety and effectiveness with the hope of eventually gaining FDA approval. As an investor, it's important to be aware of not only the number and types of drugs a pharma company has in its pipeline, but what stage of the testing and approval process those drugs fall into.
Stages of drug testing
A big reason it takes so long for drugs to get approved is that new formulas need to go through several phases of testing to ensure that they're effective and safe. There are typically four stages involved:
- Phase 1: During this initial stage of testing, a small group of volunteers (typically 20 to 100) will take a small dosage of a drug to see what, if any, side effects arise. Those who participate in phase 1 clinical trials are generally healthy individuals, though in some cases, patients with certain conditions can take part as well. Phase 1 drug trials usually last a few months and are used to determine the safest dose for a given formula.
- Phase 2: During the second stage of testing, a new formula will be tested on several hundred patients who have the condition the drug is designed to treat. Phase 2 drug tests typically last anywhere from several months to two years, and their purpose is to study a drug's efficacy as well as its side effects.
- Phase 3: During the third stage of testing, a new drug is usually tested on a few thousand patients who have the condition that it's intended to treat. Phase 3 clinical trials generally take anywhere from one to four years, and because they're conducted on more people over a lengthier period of time, they're more likely to expose long-term side effects than studies conducted during earlier testing phases. If a drug is deemed safe after the third stage of testing, the company behind it can seek FDA approval to market it to the public.
- Phase 4: The fourth stage of testing is actually carried out once a drug has been FDA-approved. This phase involves what's known as post-market safety monitoring, during which a drug's safety is further studied and evaluated based on its use by a significantly larger number of patients.
Drug pipelines and investing
As an investor, it's critical to review a pharma company's pipeline before deciding whether to buy its stock. A company might have just a few drugs in its pipeline or multiple drugs, but the key is to focus on the types of drugs and the specific stages they're at rather than fixate on quantity alone. While a large percentage of drugs, for example, fail to make it past the first phase of testing, the majority of drugs that enter phase 3 usually wind up getting FDA approval. Therefore, a company with two drugs in phase 3 might be a better buy than a company with six drugs in phase 1.
It's also important to look at the target market for the drugs a company has in its pipeline. Drugs that are designed to treat chronic conditions like diabetes and high cholesterol tend to be extremely profitable when they actually work. Similarly, breakthrough drugs -- those that succeed in treating life-threatening illness or demonstrate superiority over existing treatments -- can result in huge profits. Understanding the types of drugs a pharmaceutical company has in its pipeline and what stages those drugs are at can help you evaluate the risks and rewards of investing in its stock.
This article is part of The Motley Fool's Knowledge Center, which was created based on the collected wisdom of a fantastic community of investors. We'd love to hear your questions, thoughts, and opinions on the Knowledge Center in general or this page in particular. Your input will help us help the world invest, better! Email us at firstname.lastname@example.org . Thanks -- and Fool on!
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.